Pyxis Oncology develops site-specific conjugated antibody-drug conjugates and immuno-oncology antibodies targeting the tumor microenvironment and immune checkpoints to treat difficult-to-treat solid tumors and hematologic malignancies.

Founded 2018

Massachusetts, United States

51-100

Publicly Traded  
[pyxisoncology.com](https://pyxisoncology.com/)

## Highlights

### Focus Areas
- Biotechnology
- Health Care
- Oncology
- Pharmaceutical

### Recent Investors
- [A](/content/investor/agent-capital/index.html)  
  [R](/content/investor/ra-capital-management/index.html)  
[A](/content/investor/acuta-capital-partners/index.html)  
[R](/content/investor/ridgeback-capital-investments/index.html)  
[H](/content/investor/hbm-healthcare-investments/index.html)  
[J](/content/investor/janus-henderson-investors/index.html)  
 [A](/content/investor/arix-bioscience/index.html)  
[L](/content/investor/leaps-by-bayer/index.html)

## Financials
- **$174M** Total Raised  
- **2** Funding rounds  
- **21** Investors

## Team

### Sign up to view the team

See the team members at Pyxis Oncology.